RT Journal Article
SR Electronic
T1 Anticancer Mechanism of Plumbagin, a Natural Compound, on Non-small Cell Lung Cancer Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 785
OP 792
VO 28
IS 2A
A1 GOMATHINAYAGAM, ROHINI
A1 SOWMYALAKSHMI, SRINIVASAN
A1 MARDHATILLAH, FIRDAUS
A1 KUMAR, RAJ
A1 AKBARSHA, MOHAMMAD A.
A1 DAMODARAN, CHENDIL
YR 2008
UL http://ar.iiarjournals.org/content/28/2A/785.abstract
AB Background: Lung cancer is the leading cause of cancer-related deaths in the United States. Prevailing treatment options have limited therapeutic success in lung cancer, particularly non-small cell lung cancer (NSCLC), as it becomes resistant to therapy. Hence, better therapeutic options are immediately required for lung cancer. Plumbagin, a natural compound has been recently examined for its anticancer effect on different cancers. Materials and Methods: To determine the anticancer effect of plumbagin on NSCLC cell lines H460 and A549, cell viability, apoptotic, Western blot and reporter assays were performed. Results: Plumbagin significantly inhibited the growth of H460 cells compared to A549 cells, and down-regulated the expression of EGFR/Neu and its downstream signaling (Akt, NF-κB, Bcl-2 and survivin) in H460 cells. In addition, plumbagin up-regulated the expression of p53 and p21CIP1/WAF1 causing cell cycle arrest in the G2/M-phase by down-regulating G2/M regulatory proteins (cyclinB1 and Cdc25B) in H460 cells. Furthermore, it activated the JNK/p38 signaling, leading to caspase-3 activation resulting in the induction of apoptosis. Conclusion: Plumbagin exerted anticancer activity on NSCLC cells by modulating the pro-survival and pro-apoptotic signaling that causes induction of apoptosis.